{"transactions":[{"id":711504,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2026-07-10T22:54:36.000Z","date":"2026-07-10","kind":"sale","planned":true,"acquired":false,"shares":200000,"price":6.24,"value":1248000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.99 to $6.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":936410,"source":{"system":"sec-edgar","filing":"0001665124-26-000013","document":"form4-07102026_100732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000013/form4-07102026_100732.xml","form_type":"4"}},{"id":756121,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-02T20:30:21.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":42671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":42671,"derivative":{"exercise_price":5.97,"expiration_date":"2036-06-01","underlying":"Common Stock","underlying_shares":42671},"source":{"system":"sec-edgar","filing":"0001709418-26-000002","document":"form4-06022026_040616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000170941826000002/form4-06022026_040616.xml","form_type":"4"}},{"id":756120,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-02T20:30:21.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":21335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":1176559,"source":{"system":"sec-edgar","filing":"0001709418-26-000002","document":"form4-06022026_040616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000170941826000002/form4-06022026_040616.xml","form_type":"4"}},{"id":756117,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":39068,"kind":"person","name":"Donenberg Phillip B.","position":1,"cik":"0001238120","reported_name":"Donenberg Phillip B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-02T20:30:18.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":42671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":42671,"derivative":{"exercise_price":5.97,"expiration_date":"2036-06-01","underlying":"Common Stock","underlying_shares":42671},"source":{"system":"sec-edgar","filing":"0001238120-26-000008","document":"form4-06022026_040614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000123812026000008/form4-06022026_040614.xml","form_type":"4"}},{"id":756116,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":39068,"kind":"person","name":"Donenberg Phillip B.","position":1,"cik":"0001238120","reported_name":"Donenberg Phillip B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-02T20:30:18.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":21335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":241289,"source":{"system":"sec-edgar","filing":"0001238120-26-000008","document":"form4-06022026_040614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000123812026000008/form4-06022026_040614.xml","form_type":"4"}},{"id":756115,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42620,"kind":"person","name":"Long Alison S","position":1,"cik":"0001891712","reported_name":"Long Alison S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-02T20:30:17.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":42671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":42671,"derivative":{"exercise_price":5.97,"expiration_date":"2036-06-01","underlying":"Common Stock","underlying_shares":42671},"source":{"system":"sec-edgar","filing":"0001891712-26-000002","document":"form4-06022026_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000189171226000002/form4-06022026_040612.xml","form_type":"4"}},{"id":756114,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42620,"kind":"person","name":"Long Alison S","position":1,"cik":"0001891712","reported_name":"Long Alison S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-02T20:30:17.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":21335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":127178,"source":{"system":"sec-edgar","filing":"0001891712-26-000002","document":"form4-06022026_040612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000189171226000002/form4-06022026_040612.xml","form_type":"4"}},{"id":756113,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-02T20:30:15.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":42671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":42671,"derivative":{"exercise_price":5.97,"expiration_date":"2036-06-01","underlying":"Common Stock","underlying_shares":42671},"source":{"system":"sec-edgar","filing":"0001777421-26-000005","document":"form4-06022026_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000177742126000005/form4-06022026_040610.xml","form_type":"4"}},{"id":756112,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-02T20:30:15.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":21335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":127178,"source":{"system":"sec-edgar","filing":"0001777421-26-000005","document":"form4-06022026_040610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000177742126000005/form4-06022026_040610.xml","form_type":"4"}},{"id":810009,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-13T20:33:58.000Z","date":"2026-04-10","kind":"exercise","planned":true,"acquired":false,"shares":19021,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":455920,"derivative":{"exercise_price":1.71,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":19021},"source":{"system":"sec-edgar","filing":"0001665124-26-000011","document":"form4-04132026_080454.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000011/form4-04132026_080454.xml","form_type":"4"}},{"id":810008,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2026-04-13T20:33:58.000Z","date":"2026-04-10","kind":"sale","planned":true,"acquired":false,"shares":200000,"price":4.46,"value":892000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.335 to $4.625 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1136410,"source":{"system":"sec-edgar","filing":"0001665124-26-000011","document":"form4-04132026_080454.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000011/form4-04132026_080454.xml","form_type":"4"}},{"id":810007,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2026-04-13T20:33:58.000Z","date":"2026-04-10","kind":"exercise","planned":true,"acquired":true,"shares":19021,"price":1.71,"value":32525.91,"ownership":{"direct":true},"balance_after":1336410,"source":{"system":"sec-edgar","filing":"0001665124-26-000011","document":"form4-04132026_080454.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000011/form4-04132026_080454.xml","form_type":"4"}},{"id":916842,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-06T21:30:29.000Z","date":"2026-02-04","kind":"sale","planned":false,"acquired":false,"shares":1655,"price":4.52,"value":7480.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only."}],"balance_after":1442131,"source":{"system":"sec-edgar","filing":"0001793412-26-000012","document":"form4-02062026_040223.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000179341226000012/form4-02062026_040223.xml","form_type":"4"}},{"id":930580,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2026-01-27T21:05:16.000Z","date":"2026-01-26","kind":"sale","planned":false,"acquired":false,"shares":26918,"price":4.61,"value":124091.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive."}],"balance_after":1317389,"source":{"system":"sec-edgar","filing":"0001665124-26-000008","document":"form4-01272026_040105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000008/form4-01272026_040105.xml","form_type":"4"}},{"id":930579,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2026-01-27T21:05:16.000Z","date":"2026-01-23","kind":"sale","planned":false,"acquired":false,"shares":89132,"price":4.75,"value":423377.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3)."}],"balance_after":1344307,"source":{"system":"sec-edgar","filing":"0001665124-26-000008","document":"form4-01272026_040105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000008/form4-01272026_040105.xml","form_type":"4"}},{"id":930577,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-27T21:05:07.000Z","date":"2026-01-26","kind":"sale","planned":false,"acquired":false,"shares":41312,"price":4.61,"value":190448.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive."}],"balance_after":2908257,"source":{"system":"sec-edgar","filing":"0001569926-26-000008","document":"form4-01272026_040103.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000156992626000008/form4-01272026_040103.xml","form_type":"4"}},{"id":930576,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-27T21:05:07.000Z","date":"2026-01-23","kind":"sale","planned":false,"acquired":false,"shares":136789,"price":4.75,"value":649747.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3)."}],"balance_after":2949569,"source":{"system":"sec-edgar","filing":"0001569926-26-000008","document":"form4-01272026_040103.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000156992626000008/form4-01272026_040103.xml","form_type":"4"}},{"id":930575,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-01-27T21:05:05.000Z","date":"2026-01-26","kind":"sale","planned":false,"acquired":false,"shares":23849,"price":4.61,"value":109943.89,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive."}],"balance_after":1443786,"source":{"system":"sec-edgar","filing":"0001793412-26-000008","document":"form4-01272026_040101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000179341226000008/form4-01272026_040101.xml","form_type":"4"}},{"id":930574,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-01-27T21:05:05.000Z","date":"2026-01-23","kind":"sale","planned":false,"acquired":false,"shares":78968,"price":4.75,"value":375098.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3)."}],"balance_after":1467635,"source":{"system":"sec-edgar","filing":"0001793412-26-000008","document":"form4-01272026_040101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000179341226000008/form4-01272026_040101.xml","form_type":"4"}},{"id":939690,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-14T21:45:10.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":231000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":231000,"derivative":{"exercise_price":4.86,"expiration_date":"2036-01-12","underlying":"Common Stock","underlying_shares":231000},"source":{"system":"sec-edgar","filing":"0001793412-26-000002","document":"form4-01142026_040105.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000179341226000002/form4-01142026_040105.xml","form_type":"4"}},{"id":939689,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-01-14T21:45:10.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":359000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":1546603,"source":{"system":"sec-edgar","filing":"0001793412-26-000002","document":"form4-01142026_040105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000179341226000002/form4-01142026_040105.xml","form_type":"4"}},{"id":939688,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-14T21:45:09.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":648000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":648000,"derivative":{"exercise_price":4.86,"expiration_date":"2036-01-12","underlying":"Common Stock","underlying_shares":648000},"source":{"system":"sec-edgar","filing":"0001569926-26-000002","document":"form4-01142026_040103.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000156992626000002/form4-01142026_040103.xml","form_type":"4"}},{"id":939687,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:45:09.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":1008000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":3086358,"source":{"system":"sec-edgar","filing":"0001569926-26-000002","document":"form4-01142026_040103.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000156992626000002/form4-01142026_040103.xml","form_type":"4"}},{"id":939686,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-14T21:45:07.000Z","date":"2026-01-12","kind":"grant","planned":true,"acquired":true,"shares":274000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":274000,"derivative":{"exercise_price":4.86,"expiration_date":"2036-01-12","underlying":"Common Stock","underlying_shares":274000},"source":{"system":"sec-edgar","filing":"0001665124-26-000002","document":"form4-01142026_040101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000002/form4-01142026_040101.xml","form_type":"4"}},{"id":939685,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-14T21:45:07.000Z","date":"2026-01-12","kind":"exercise","planned":true,"acquired":false,"shares":88676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":474941,"derivative":{"exercise_price":1.71,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":88676},"source":{"system":"sec-edgar","filing":"0001665124-26-000002","document":"form4-01142026_040101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000002/form4-01142026_040101.xml","form_type":"4"}},{"id":939684,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-14T21:45:07.000Z","date":"2026-01-12","kind":"exercise","planned":true,"acquired":false,"shares":111324,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":111359,"derivative":{"exercise_price":0.6989,"expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":111324},"source":{"system":"sec-edgar","filing":"0001665124-26-000002","document":"form4-01142026_040101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000002/form4-01142026_040101.xml","form_type":"4"}},{"id":939683,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:45:07.000Z","date":"2026-01-12","kind":"grant","planned":true,"acquired":true,"shares":427000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":1433439,"source":{"system":"sec-edgar","filing":"0001665124-26-000002","document":"form4-01142026_040101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000002/form4-01142026_040101.xml","form_type":"4"}},{"id":939682,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:45:07.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":200000,"price":4.71,"value":942000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.565 to $4.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1006439,"source":{"system":"sec-edgar","filing":"0001665124-26-000002","document":"form4-01142026_040101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000002/form4-01142026_040101.xml","form_type":"4"}},{"id":939681,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:45:07.000Z","date":"2026-01-12","kind":"exercise","planned":true,"acquired":true,"shares":88676,"price":1.71,"value":151635.96,"ownership":{"direct":true},"balance_after":1206439,"source":{"system":"sec-edgar","filing":"0001665124-26-000002","document":"form4-01142026_040101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000002/form4-01142026_040101.xml","form_type":"4"}},{"id":939680,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:45:07.000Z","date":"2026-01-12","kind":"exercise","planned":true,"acquired":true,"shares":111324,"price":0.6989,"value":77804.3436,"ownership":{"direct":true},"balance_after":1117763,"source":{"system":"sec-edgar","filing":"0001665124-26-000002","document":"form4-01142026_040101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000002/form4-01142026_040101.xml","form_type":"4"}},{"id":985787,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-02T01:58:44.000Z","date":"2025-12-01","kind":"exercise","planned":false,"acquired":false,"shares":260047,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":563617,"derivative":{"exercise_price":1.71,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":260047},"source":{"system":"sec-edgar","filing":"0001665124-25-000003","document":"form4-12022025_011240.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512425000003/form4-12022025_011240.xml","form_type":"4"}},{"id":985786,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-02T01:58:44.000Z","date":"2025-11-28","kind":"exercise","planned":false,"acquired":false,"shares":39953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":823664,"derivative":{"exercise_price":1.71,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":39953},"source":{"system":"sec-edgar","filing":"0001665124-25-000003","document":"form4-12022025_011240.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512425000003/form4-12022025_011240.xml","form_type":"4"}},{"id":985785,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-02T01:58:44.000Z","date":"2025-11-28","kind":"exercise","planned":false,"acquired":false,"shares":70172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":222683,"derivative":{"exercise_price":0.6989,"expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":70172},"source":{"system":"sec-edgar","filing":"0001665124-25-000003","document":"form4-12022025_011240.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512425000003/form4-12022025_011240.xml","form_type":"4"}},{"id":985784,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2025-12-02T01:58:44.000Z","date":"2025-12-01","kind":"sale","planned":false,"acquired":false,"shares":260047,"price":4.51,"value":1172811.97,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.42 to $4.63 inclusive."}],"balance_after":1006439,"source":{"system":"sec-edgar","filing":"0001665124-25-000003","document":"form4-12022025_011240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512425000003/form4-12022025_011240.xml","form_type":"4"}},{"id":985783,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2025-12-02T01:58:44.000Z","date":"2025-12-01","kind":"exercise","planned":false,"acquired":true,"shares":260047,"price":1.71,"value":444680.37,"ownership":{"direct":true},"balance_after":1266486,"source":{"system":"sec-edgar","filing":"0001665124-25-000003","document":"form4-12022025_011240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512425000003/form4-12022025_011240.xml","form_type":"4"}},{"id":985782,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2025-12-02T01:58:44.000Z","date":"2025-11-28","kind":"sale","planned":false,"acquired":false,"shares":110125,"price":4.75,"value":523093.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.7248 to $4.8348 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2)."}],"balance_after":1006439,"source":{"system":"sec-edgar","filing":"0001665124-25-000003","document":"form4-12022025_011240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512425000003/form4-12022025_011240.xml","form_type":"4"}},{"id":985781,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2025-12-02T01:58:44.000Z","date":"2025-11-28","kind":"exercise","planned":false,"acquired":true,"shares":39953,"price":1.71,"value":68319.63,"ownership":{"direct":true},"balance_after":1116564,"source":{"system":"sec-edgar","filing":"0001665124-25-000003","document":"form4-12022025_011240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512425000003/form4-12022025_011240.xml","form_type":"4"}},{"id":985780,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2025-12-02T01:58:44.000Z","date":"2025-11-28","kind":"exercise","planned":false,"acquired":true,"shares":70172,"price":0.6989,"value":49043.2108,"ownership":{"direct":true},"balance_after":1076611,"source":{"system":"sec-edgar","filing":"0001665124-25-000003","document":"form4-12022025_011240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512425000003/form4-12022025_011240.xml","form_type":"4"}},{"id":1042244,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-12T20:15:25.000Z","date":"2025-09-10","kind":"exercise","planned":true,"acquired":false,"shares":41150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":292855,"derivative":{"exercise_price":0.6989,"expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":41150},"source":{"system":"sec-edgar","filing":"0001415889-25-024369","document":"form4-09122025_040917.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925024369/form4-09122025_040917.xml","form_type":"4"}},{"id":1042243,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2025-09-12T20:15:25.000Z","date":"2025-09-10","kind":"sale","planned":true,"acquired":false,"shares":200000,"price":3.23,"value":646000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.165 to $3.31 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1006439,"source":{"system":"sec-edgar","filing":"0001415889-25-024369","document":"form4-09122025_040917.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925024369/form4-09122025_040917.xml","form_type":"4"}},{"id":1042242,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2025-09-12T20:15:25.000Z","date":"2025-09-10","kind":"exercise","planned":true,"acquired":true,"shares":41150,"price":0.6989,"value":28759.735,"ownership":{"direct":true},"balance_after":1206439,"source":{"system":"sec-edgar","filing":"0001415889-25-024369","document":"form4-09122025_040917.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925024369/form4-09122025_040917.xml","form_type":"4"}},{"id":1058792,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2025-08-22T20:15:17.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":57054,"price":2.85,"value":162603.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.841 to $2.865 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1165289,"source":{"system":"sec-edgar","filing":"0001415889-25-022750","document":"form4-08222025_040806.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925022750/form4-08222025_040806.xml","form_type":"4"}},{"id":1058791,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-08-22T20:15:08.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":54491,"price":2.85,"value":155299.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.841 to $2.865 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1187603,"source":{"system":"sec-edgar","filing":"0001415889-25-022749","document":"form4-08222025_040804.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925022749/form4-08222025_040804.xml","form_type":"4"}},{"id":1123811,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-04T20:15:26.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":113246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":113246,"derivative":{"exercise_price":2.785,"expiration_date":"2035-06-02","underlying":"Common Stock","underlying_shares":113246},"source":{"system":"sec-edgar","filing":"0001415889-25-015574","document":"form4-06042025_040609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925015574/form4-06042025_040609.xml","form_type":"4"}},{"id":1123810,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-04T20:15:26.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":56623,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":1155224,"source":{"system":"sec-edgar","filing":"0001415889-25-015574","document":"form4-06042025_040609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925015574/form4-06042025_040609.xml","form_type":"4"}},{"id":1123809,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":39068,"kind":"person","name":"Donenberg Phillip B.","position":1,"cik":"0001238120","reported_name":"Donenberg Phillip B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-04T20:15:20.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":113246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":113246,"derivative":{"exercise_price":2.785,"expiration_date":"2035-06-02","underlying":"Common Stock","underlying_shares":113246},"source":{"system":"sec-edgar","filing":"0001415889-25-015573","document":"form4-06042025_040607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925015573/form4-06042025_040607.xml","form_type":"4"}},{"id":1123808,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":39068,"kind":"person","name":"Donenberg Phillip B.","position":1,"cik":"0001238120","reported_name":"Donenberg Phillip B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-04T20:15:20.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":56623,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":219954,"source":{"system":"sec-edgar","filing":"0001415889-25-015573","document":"form4-06042025_040607.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925015573/form4-06042025_040607.xml","form_type":"4"}},{"id":1123807,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42620,"kind":"person","name":"Long Alison S","position":1,"cik":"0001891712","reported_name":"Long Alison S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-04T20:15:15.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":113246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":113246,"derivative":{"exercise_price":2.785,"expiration_date":"2035-06-02","underlying":"Common Stock","underlying_shares":113246},"source":{"system":"sec-edgar","filing":"0001415889-25-015572","document":"form4-06042025_040604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925015572/form4-06042025_040604.xml","form_type":"4"}},{"id":1123806,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42620,"kind":"person","name":"Long Alison S","position":1,"cik":"0001891712","reported_name":"Long Alison S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-04T20:15:15.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":56623,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":105843,"source":{"system":"sec-edgar","filing":"0001415889-25-015572","document":"form4-06042025_040604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925015572/form4-06042025_040604.xml","form_type":"4"}},{"id":1123805,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-04T20:15:11.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":113246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":113246,"derivative":{"exercise_price":2.785,"expiration_date":"2035-06-02","underlying":"Common Stock","underlying_shares":113246},"source":{"system":"sec-edgar","filing":"0001415889-25-015571","document":"form4-06042025_040601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925015571/form4-06042025_040601.xml","form_type":"4"}},{"id":1123804,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-04T20:15:11.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":56623,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":105843,"source":{"system":"sec-edgar","filing":"0001415889-25-015571","document":"form4-06042025_040601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925015571/form4-06042025_040601.xml","form_type":"4"}},{"id":1126544,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-04T01:38:27.000Z","date":"2025-05-30","kind":"purchase","planned":false,"acquired":true,"shares":750000,"price":2.75,"value":2062500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":2841704,"source":{"system":"sec-edgar","filing":"0001415889-25-015480","document":"form4-06042025_010624.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925015480/form4-06042025_010624.xml","form_type":"4"}},{"id":1174422,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-10T20:15:13.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":12462,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was awarded on February 2, 2023 by the Compensation Committee (the \"Compensation Committee\") of the Issuer's Board of Directors as annual incentive compensation for 2022 performance. On May 31, 2023, the Compensation Committee certified the achievement of a certain performance goal. The shares underlying the option covered by this report vested upon certification. This option was inadvertently omitted for the original Form 4."}],"balance_after":12462,"derivative":{"exercise_price":1.18,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":12462},"source":{"system":"sec-edgar","filing":"0001415889-25-010539","document":"form4a-04102025_040408.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925010539/form4a-04102025_040408.xml","form_type":"4/A","original_submission_date":"2023-06-02"}},{"id":1208609,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-03-13T20:15:05.000Z","date":"2025-03-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":29843,"price":1.69,"value":50434.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the tax withholding obligations triggered by the vesting and settlement of restricted stock units and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":1242094,"source":{"system":"sec-edgar","filing":"0001415889-25-007997","document":"form4-03132025_040301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925007997/form4-03132025_040301.xml","form_type":"4"}},{"id":1317457,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-03T22:38:40.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":892500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2026 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":892500,"derivative":{"exercise_price":1.85,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":892500},"source":{"system":"sec-edgar","filing":"0001415889-25-000599","document":"form4-01032025_100137.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925000599/form4-01032025_100137.xml","form_type":"4"}},{"id":1317456,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-03T22:38:40.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":892500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSU grant was approved by the Issuer's compensation committee of the board of directors and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares available for issuance under the 2020 Stock Incentive Plan. The RSUs will vest in four equal annual installments beginning on January 2, 2026, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":2078358,"source":{"system":"sec-edgar","filing":"0001415889-25-000599","document":"form4-01032025_100137.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925000599/form4-01032025_100137.xml","form_type":"4"}},{"id":1317455,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-03T22:36:40.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":324500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2026 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":324500,"derivative":{"exercise_price":1.85,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":324500},"source":{"system":"sec-edgar","filing":"0001415889-25-000597","document":"form4-01032025_100136.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925000597/form4-01032025_100136.xml","form_type":"4"}},{"id":1317454,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2025-01-03T22:36:40.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":324500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSU grant was approved by the Issuer's compensation committee of the board of directors and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares\navailable for issuance under the 2020 Stock Incentive Plan. The RSUs will vest in four equal annual installments beginning on January 2, 2026, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":1222343,"source":{"system":"sec-edgar","filing":"0001415889-25-000597","document":"form4-01032025_100136.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925000597/form4-01032025_100136.xml","form_type":"4"}},{"id":1317453,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-03T22:31:21.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":431000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2026 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":431000,"derivative":{"exercise_price":1.85,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":431000},"source":{"system":"sec-edgar","filing":"0001415889-25-000595","document":"form4-01032025_100118.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925000595/form4-01032025_100118.xml","form_type":"4"}},{"id":1317452,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-01-03T22:31:21.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":431000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSU grant was approved by the Issuer's compensation committee of the board of directors and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares available for issuance under the 2020 Stock Incentive Plan. The RSUs will vest in four equal annual installments beginning on January 2, 2026, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":1271937,"source":{"system":"sec-edgar","filing":"0001415889-25-000595","document":"form4-01032025_100118.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925000595/form4-01032025_100118.xml","form_type":"4"}},{"id":1466672,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-01T12:00:07.000Z","date":"2024-06-27","kind":"purchase","planned":false,"acquired":true,"shares":1333333,"price":2.25,"value":2999999.25,"ownership":{"direct":true},"balance_after":1333333,"source":{"system":"sec-edgar","filing":"0001415889-24-018515","document":"form4-07012024_080703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588924018515/form4-07012024_080703.xml","form_type":"4"}},{"id":1497243,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-31T20:18:25.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":98440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":98440,"derivative":{"exercise_price":3.17,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":98440},"source":{"system":"sec-edgar","filing":"0001415889-24-015041","document":"form4-05312024_040510.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588924015041/form4-05312024_040510.xml","form_type":"4"}},{"id":1497242,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-31T20:18:25.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":49220,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":1098601,"source":{"system":"sec-edgar","filing":"0001415889-24-015041","document":"form4-05312024_040510.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588924015041/form4-05312024_040510.xml","form_type":"4"}},{"id":1497241,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42620,"kind":"person","name":"Long Alison S","position":1,"cik":"0001891712","reported_name":"Long Alison S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-31T20:18:23.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":98440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":98440,"derivative":{"exercise_price":3.17,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":98440},"source":{"system":"sec-edgar","filing":"0001415889-24-015040","document":"form4-05312024_040508.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588924015040/form4-05312024_040508.xml","form_type":"4"}},{"id":1497240,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42620,"kind":"person","name":"Long Alison S","position":1,"cik":"0001891712","reported_name":"Long Alison S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-31T20:18:23.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":49220,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":49220,"source":{"system":"sec-edgar","filing":"0001415889-24-015040","document":"form4-05312024_040508.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588924015040/form4-05312024_040508.xml","form_type":"4"}},{"id":1497239,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":39068,"kind":"person","name":"Donenberg Phillip B.","position":1,"cik":"0001238120","reported_name":"Donenberg Phillip B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-31T20:18:21.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":98440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":98440,"derivative":{"exercise_price":3.17,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":98440},"source":{"system":"sec-edgar","filing":"0001415889-24-015039","document":"form4-05312024_040505.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588924015039/form4-05312024_040505.xml","form_type":"4"}},{"id":1497238,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":39068,"kind":"person","name":"Donenberg Phillip B.","position":1,"cik":"0001238120","reported_name":"Donenberg Phillip B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-31T20:18:21.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":49220,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":163331,"source":{"system":"sec-edgar","filing":"0001415889-24-015039","document":"form4-05312024_040505.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588924015039/form4-05312024_040505.xml","form_type":"4"}},{"id":1497237,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-31T20:15:09.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":98440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":98440,"derivative":{"exercise_price":3.17,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":98440},"source":{"system":"sec-edgar","filing":"0001415889-24-015038","document":"form4-05312024_040501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588924015038/form4-05312024_040501.xml","form_type":"4"}},{"id":1497236,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-31T20:15:09.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":49220,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":49220,"source":{"system":"sec-edgar","filing":"0001415889-24-015038","document":"form4-05312024_040501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588924015038/form4-05312024_040501.xml","form_type":"4"}},{"id":1657583,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-06T21:42:03.000Z","date":"2024-02-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":1288,"price":1.51,"value":1944.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":840937,"source":{"system":"sec-edgar","filing":"0001415889-24-002809","document":"form4-02062024_090255.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588924002809/form4-02062024_090255.xml","form_type":"4"}},{"id":1689765,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-04T21:43:04.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":590413,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2025 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":590413,"derivative":{"exercise_price":1.71,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":590413},"source":{"system":"sec-edgar","filing":"0001209191-24-000811","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919124000811/doc4.xml","form_type":"4"}},{"id":1689764,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-04T21:43:04.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":590413,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award.  The RSUs will vest in four equal annual installments beginning on January 2, 2025, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":842225,"source":{"system":"sec-edgar","filing":"0001209191-24-000811","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919124000811/doc4.xml","form_type":"4"}},{"id":1689763,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-04T21:42:30.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":863617,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2025 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":863617,"derivative":{"exercise_price":1.71,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":863617},"source":{"system":"sec-edgar","filing":"0001209191-24-000809","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919124000809/doc4.xml","form_type":"4"}},{"id":1689762,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2024-01-04T21:42:30.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":863617,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award.  The RSUs will vest in four equal annual installments beginning on January 2, 2025, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":897843,"source":{"system":"sec-edgar","filing":"0001209191-24-000809","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919124000809/doc4.xml","form_type":"4"}},{"id":1689761,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-04T21:41:35.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":1184688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2025 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":1184688,"derivative":{"exercise_price":1.71,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":1184688},"source":{"system":"sec-edgar","filing":"0001209191-24-000807","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919124000807/doc4.xml","form_type":"4"}},{"id":1689760,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-04T21:41:35.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":1184688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award.  The RSUs will vest in four equal annual installments beginning on January 2, 2025, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":1185858,"source":{"system":"sec-edgar","filing":"0001209191-24-000807","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919124000807/doc4.xml","form_type":"4"}},{"id":1708251,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-12-18T21:50:32.000Z","date":"2023-12-14","kind":"grant","planned":false,"acquired":true,"shares":187582,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The compensation committee of the board of directors of the Issuer certified achievement of certain performance criteria such that 70% of the option shares subject to the performance-based stock option award were earned. The shares underlying the earned potion of the option shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":187582,"derivative":{"exercise_price":0.6989,"expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":187582},"source":{"system":"sec-edgar","filing":"0001209191-23-058977","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123058977/doc4.xml","form_type":"4"}},{"id":1708250,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-12-18T21:47:23.000Z","date":"2023-12-14","kind":"grant","planned":false,"acquired":true,"shares":334005,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The compensation committee of the board of directors of the Issuer certified achievement of certain performance criteria such that 70% of the option shares subject to the performance-based stock option award were earned. The shares underlying the earned potion of the option shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":334005,"derivative":{"exercise_price":0.6989,"expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":334005},"source":{"system":"sec-edgar","filing":"0001209191-23-058973","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123058973/doc4.xml","form_type":"4"}},{"id":1708249,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-12-18T21:46:29.000Z","date":"2023-12-14","kind":"grant","planned":false,"acquired":true,"shares":466550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The compensation committee of the board of directors of the Issuer certified achievement of certain performance criteria such that 70% of the option shares subject to the performance-based stock option award were earned. The shares underlying the earned potion of the option shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":466550,"derivative":{"exercise_price":0.6989,"expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":466550},"source":{"system":"sec-edgar","filing":"0001209191-23-058971","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123058971/doc4.xml","form_type":"4"}},{"id":1735480,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-20T12:35:02.000Z","date":"2023-11-17","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":1.63,"value":163000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.57 to $1.68 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Revocable Trust\"). The Reporting Person is the trustee of the Revocable Trust and has sole voting and investment power with respect to the shares held by the Revocable Trust."}],"balance_after":16566667,"source":{"system":"sec-edgar","filing":"0001209191-23-055942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123055942/doc4.xml","form_type":"4"}},{"id":1750751,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42620,"kind":"person","name":"Long Alison S","position":1,"cik":"0001891712","reported_name":"Long Alison S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-11-03T20:41:56.000Z","date":"2023-11-01","kind":"grant","planned":false,"acquired":true,"shares":43800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest in 36 equal monthly installments commencing on December 1, 2023 such that the shares will be fully vested on November 1, 2026, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":43800,"derivative":{"exercise_price":2.385,"expiration_date":"2033-11-01","underlying":"Common Stock","underlying_shares":43800},"source":{"system":"sec-edgar","filing":"0001209191-23-054339","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123054339/doc4.xml","form_type":"4"}},{"id":1797146,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-25T20:30:47.000Z","date":"2023-08-24","kind":"sale","planned":true,"acquired":false,"shares":33000,"price":2.33,"value":76890.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a mandatory \"sell to cover\" arrangement adopted by the Reporting Person on May 26, 2023 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.185 to $2.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":258042,"source":{"system":"sec-edgar","filing":"0001209191-23-047323","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123047323/doc4.xml","form_type":"4"}},{"id":1806746,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T00:57:08.000Z","date":"2023-08-16","kind":"purchase","planned":false,"acquired":true,"shares":16466667,"price":0.9,"value":14820000.3,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The change in the total shares held prior to the transactions reported herein reflects a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Revocable Trust\"). The Reporting Person is the trustee of the Revocable Trust and has sole voting and investment power with respect to the shares held by the Revocable Trust."}],"balance_after":16466667,"source":{"system":"sec-edgar","filing":"0001209191-23-046154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123046154/doc4.xml","form_type":"4"}},{"id":1806744,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T00:53:51.000Z","date":"2023-08-16","kind":"gift","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1049381,"source":{"system":"sec-edgar","filing":"0001209191-23-046152","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123046152/doc4.xml","form_type":"4"}},{"id":1806743,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T00:53:51.000Z","date":"2023-08-16","kind":"purchase","planned":false,"acquired":true,"shares":388889,"price":0.9,"value":350000.1,"ownership":{"direct":true},"balance_after":999381,"source":{"system":"sec-edgar","filing":"0001209191-23-046152","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123046152/doc4.xml","form_type":"4"}},{"id":1806742,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T00:53:51.000Z","date":"2023-08-16","kind":"purchase","planned":false,"acquired":true,"shares":388889,"price":0.9,"value":350000.1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018."}],"balance_after":884290,"source":{"system":"sec-edgar","filing":"0001209191-23-046152","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123046152/doc4.xml","form_type":"4"}},{"id":1806745,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-08-17T00:52:21.000Z","date":"2023-08-16","kind":"purchase","planned":false,"acquired":true,"shares":444444,"price":0.9,"value":399999.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Nolan Capital, LLC (the \"LLC\"). The Reporting Person is the President of the LLC and has shared voting and investment power with respect to the shares held by the LLC."}],"balance_after":1535545,"source":{"system":"sec-edgar","filing":"0001209191-23-046150","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123046150/doc4.xml","form_type":"4"}},{"id":1806741,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":39068,"kind":"person","name":"Donenberg Phillip B.","position":1,"cik":"0001238120","reported_name":"Donenberg Phillip B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T00:51:19.000Z","date":"2023-08-16","kind":"purchase","planned":false,"acquired":true,"shares":111111,"price":0.9,"value":99999.9,"ownership":{"direct":true},"balance_after":114111,"source":{"system":"sec-edgar","filing":"0001209191-23-046148","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123046148/doc4.xml","form_type":"4"}},{"id":1829897,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-14T20:00:39.000Z","date":"2023-07-13","kind":"sale","planned":false,"acquired":false,"shares":5344,"price":0.7,"value":3740.8,"ownership":{"direct":true},"balance_after":8871747,"source":{"system":"sec-edgar","filing":"0000950170-23-032986","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000095017023032986/ownership.xml","form_type":"4"}},{"id":1829896,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-14T20:00:39.000Z","date":"2023-07-12","kind":"sale","planned":false,"acquired":false,"shares":80528,"price":0.7082,"value":57029.9296,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.73. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":8877091,"source":{"system":"sec-edgar","filing":"0000950170-23-032986","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000095017023032986/ownership.xml","form_type":"4"}},{"id":1844707,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-26T20:50:51.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":36200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the earlier of June 22, 2024 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":36200,"derivative":{"exercise_price":0.72,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":36200},"source":{"system":"sec-edgar","filing":"0001209191-23-039733","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123039733/doc4.xml","form_type":"4"}},{"id":1844706,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":111946,"kind":"person","name":"Reape Kathleen","position":1,"cik":"0001832203","reported_name":"Reape Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-26T20:50:09.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":36200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the earlier of June 22, 2024 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":36200,"derivative":{"exercise_price":0.72,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":36200},"source":{"system":"sec-edgar","filing":"0001209191-23-039732","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123039732/doc4.xml","form_type":"4"}},{"id":1844705,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":39068,"kind":"person","name":"Donenberg Phillip B.","position":1,"cik":"0001238120","reported_name":"Donenberg Phillip B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-26T20:49:29.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":36200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the earlier of June 22, 2024 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":36200,"derivative":{"exercise_price":0.72,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":36200},"source":{"system":"sec-edgar","filing":"0001209191-23-039731","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123039731/doc4.xml","form_type":"4"}},{"id":1844704,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-26T20:48:53.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":43800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the earlier of June 22, 2024 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":43800,"derivative":{"exercise_price":0.72,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":43800},"source":{"system":"sec-edgar","filing":"0001209191-23-039730","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123039730/doc4.xml","form_type":"4"}},{"id":1844703,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-26T20:46:19.000Z","date":"2023-06-23","kind":"sale","planned":false,"acquired":false,"shares":18100,"price":0.7036,"value":12735.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.716. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":8957619,"source":{"system":"sec-edgar","filing":"0000899243-23-016491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000089924323016491/doc4.xml","form_type":"4"}},{"id":1844702,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-26T20:46:19.000Z","date":"2023-06-22","kind":"sale","planned":false,"acquired":false,"shares":10508,"price":0.7027,"value":7383.9716,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.7185. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":8975719,"source":{"system":"sec-edgar","filing":"0000899243-23-016491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000089924323016491/doc4.xml","form_type":"4"}},{"id":1847246,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-22T20:00:11.000Z","date":"2023-06-21","kind":"sale","planned":false,"acquired":false,"shares":138962,"price":0.7026,"value":97634.7012,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.719. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":8986227,"source":{"system":"sec-edgar","filing":"0000899243-23-016232","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000089924323016232/doc4.xml","form_type":"4"}},{"id":1847245,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-22T20:00:11.000Z","date":"2023-06-20","kind":"sale","planned":false,"acquired":false,"shares":295653,"price":0.711,"value":210209.283,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.78. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":9125189,"source":{"system":"sec-edgar","filing":"0000899243-23-016232","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000089924323016232/doc4.xml","form_type":"4"}},{"id":1871191,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-02T20:12:47.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":6230,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a performance restricted stock unit (\"PRSU\") award. The PRSUs were awarded on February 2, 2023 by the Compensation Committee (the \"Compensation Committee\") of the Issuer's Board of Directors as annual incentive compensation for 2022 performance. On May 31, 2023, the Compensation Committee certified the achievement of a certain performance goal. The PRSUs covered by this report vested upon certification."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each PRSU represented a contingent right to receive one share the Issuer's common stock."}],"balance_after":291042,"source":{"system":"sec-edgar","filing":"0001209191-23-033681","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123033681/doc4.xml","form_type":"4"}},{"id":1887781,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2023-05-18T20:44:26.000Z","date":"2023-05-16","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":0.68,"value":3400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.682 to $0.6879 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":34226,"source":{"system":"sec-edgar","filing":"0001209191-23-030661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123030661/doc4.xml","form_type":"4"}}],"next_cursor":"2023-05-18T20:44:26.000000Z,1887781"}